Table 4 Comparison of IC50 values (µM) of temozolomide (TMZ) treatment (48 h exposition) in two stabilized glioma cells U87MG and its STAT3 KO variant. Endpoint detection was performed using WST-1 analysis
From: Expression of STAT3 and hypoxia markers in long-term surviving malignant glioma patients
glioma cell line | Proliferation [%] | TMZ [µM] |
|---|---|---|
U87MG IDH1wt | 100.00 ± 14.13 | 3056.00 |
U87MG STAT3KO | 132.37 ± 20.89 | 4138.00* |